1-异丙基-4-(5-硝基吡啶-2-基)哌嗪 | 889851-51-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 1-异丙基-4-(5-硝基吡啶-2-基)哌嗪
• 英文名称: 1-isopropyl-4-(5-nitropyridin-2-yl)piperazine
• 英文别名: 1-Isopropyl-4-(5-nitro-pyridin-2-yl)-piperazine；1-(5-nitropyridin-2-yl)-4-propan-2-ylpiperazine
• CAS: 889851-51-8
• 化学式: C₁₂H₁₈N₄O₂
• 分子量: 250.301
• InChiKey: FPNLLWSCRGPLGJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  65.2
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  1-异丙基-4-(5-硝基吡啶-2-基)哌嗪 在 palladium on activated charcoal 、 氢气 、 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 20.0 ℃ 、101.33 kPa 条件下， 反应 24.0h， 生成 N-(6-(4-isopropylpiperazin-1-yl)pyridin-3-yl)-4-(pyridin-2-yl)benzamide
  参考文献：
  名称：

  Towards Optimization of Arylamides As Novel, Potent, and Brain-Penetrant Antiprion Lead Compounds

  摘要：

  The prion diseases caused by PrPSc, in alternatively folded form of the cellular prion protein (PrPC), are rapidly progressive, fatal, and untreatable neurodegenerative disorders. We employed HTS ELISA assays to identify compounds that lower the level of PrPSc in prion-infected mouse neuroblastoma (ScN2a-cl3) cells and identified a series of arylamides. Structure-activity relationship (SAR) studies indicated that small amides with one aromatic or heteroaromatic ring on each side of the amide bond are of modest potency. Of note, benzamide (7), with an EC50 of 2200 nM, was one of only a few arylamide hits with a piperazine group on its aniline moiety. The basic piperazine nitrogen can be protonated at physiologic pH, improving solubility, and therefore, we wanted to exploit this feature in our search for a drug candidate. An SAR campaign resulted in several key analogues, including a set with biaryl groups introduced on the carbonyl side for improved potency. Several of these biaryl analogues have submicromolar potency, with the most potent analogue 17 having an EC50 = 22 nM. More importantly, 17 and several biarylamides (20, 24, 26, and 27) Were able to traverse the blood-brain barrier.(BBB) and displayed excellent drug levels in the brains of mice following oral dosing. These biarylamides, may represent good starting points for further lead optimization for the identification of potential drug candidates for the treatment of priori diseases.

  DOI：

  10.1021/ml300454k
• 作为产物：
  描述：

  1-异丙基哌嗪 、 2-氯-5-硝基吡啶 在 potassium carbonate 作用下， 以 乙腈 为溶剂， 生成 1-异丙基-4-(5-硝基吡啶-2-基)哌嗪
  参考文献：
  名称：

  细胞周期蛋白依赖性激酶 7 和 9 强效抑制剂的发现：设计、合成、构效关系分析和生物学评价

  摘要：

  两个靶点：4-(咪唑并[1,2- a ]嘧啶-3-基)- N -吡啶基嘧啶-2-胺被发现不仅是细胞周期蛋白依赖性激酶 (CDK) 7 和 9 的有效抑制剂，而且还有效针对一系列人类癌细胞系的抗增殖剂。细胞机制研究的结果支持观察到的抗增殖作用可能源于两种 CDK 的抑制。该手稿的先前版本已存放在预印本服务器上 (https://doi.org/10.2139/ssrn.4210989 ).

  DOI：

  10.1002/cmdc.202200582

文献信息

• [EN] DERIVATIVES OF QUINOLINES AND QUINOXALINES AS PROTEIN TYROSINE KINASE INHIBITORS<br/>[FR] DÉRIVÉS DE QUINOLÉINES ET DE QUINOXALINES EN TANT QU'INHIBITEURS DE PROTÉINE TYROSINE KINASES
  申请人：NOVARTIS AG

  公开号：WO2009141386A1

  公开（公告）日：2009-11-26

  The invention relates to compounds of Formula (I), wherein the substituens are as defined in the specification, in free form or in the form of a pharmaceutically acceptable salt, solvate, ester, N-oxide thereof; processes for the preparation thereof; to pharmaceuticals containing such compounds, in particular for the use in one or more Protein tyrosine kinase mediated diseases.

  该发明涉及式（I）的化合物，其中取代基如规范中定义的那样，以自由形式或作为药用盐、溶剂合物、酯、其N-氧化物的形式存在；其制备方法；含有这种化合物的药物，特别是用于治疗一个或多个蛋白酪氨酸激酶介导的疾病。
• [EN] 2-AMINOPYRIMIDINE AND 2-AMINOPYRIDINE-4-CARBAMATES FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES<br/>[FR] 2-AMINOPYRIMIDINE ET 2-AMINOPYRIDINE-4-CARBAMATES DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DE MALADIES AUTO-IMMUNES
  申请人：AMGEN INC

  公开号：WO2005009978A1

  公开（公告）日：2005-02-03

  The present invention relates to pyrimidine or pyridine carbamate compounds having the general Formula (1) and pharmaceutically acceptable salts or derivatives thereof. Also included are methods of treatment of various diseases and conditions, including inflammation, inhibition of T cell activation and proliferation, arthritis, organ transplant, ischemic or reperfusion injury, myocardial infarction, stroke, multiple sclerosis, inflammatory bowel disease, Crohn's disease, lupus, hypersensitivity, type 1 diabetes, psoriasis, dermatitis, Hashimoto's thyroiditis, Sjogren's syndrome, autoimmune hyperthyroidism, Addison's disease, autoimmune diseases, glomerulonephritis, allergic diseases, asthma, hayfever, eczema, cancer, colon carcinoma, thymoma, just to name a few, in a mammal, the methods comprising administering a therapeutically-effective amount a compound of Formula I, or a salt or derivative form thereof, as described above.

  本发明涉及具有通用式（1）的嘧啶或吡啶羰酸酯化合物及其药用可接受的盐或衍生物。还包括治疗各种疾病和症状的方法，包括炎症、抑制T细胞激活和增殖、关节炎、器官移植、缺血或再灌注损伤、心肌梗死、中风、多发性硬化、炎症性肠病、克罗恩病、狼疮、过敏、1型糖尿病、牛皮癣、皮炎、桥本氏甲状腺炎、干燥综合征、自身免疫性甲状腺功能亢进症、艾迪生病、自身免疫疾病、肾小球肾炎、过敏性疾病、哮喘、花粉症、湿疹、癌症、结肠癌、胸腺瘤等，在哺乳动物中的方法，包括给予通用式I的化合物的治疗有效量，或如上所述的盐或衍生物形式。
• Pyridine derivatives as H3 antagonists
  申请人：Nettekoven Heinrich Matthias

  公开号：US20060122187A1

  公开（公告）日：2006-06-08

  The present invention relates to compounds of formula I wherein R 1 , R 2 and A are as defined in the description and claims, and pharmaceutically acceptable salts thereof as well as to pharmaceutical composition comprising these compounds and to methods for their preparation. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.

  本发明涉及公式I中的化合物，其中R1、R2和A如描述和权利要求中定义，以及其药学上可接受的盐，以及包含这些化合物的药物组合物以及其制备方法。这些化合物可用于治疗和/或预防与H3受体调节相关的疾病。
• Triazolopyrazine compounds useful for the treatment of degenerative & inflammatory diseases
  申请人：Andrews Inglis Martin James

  公开号：US20080090818A1

  公开（公告）日：2008-04-17

  Novel [1.2.4]triazolo[1,5-a]pyrazine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, and others.

  本发明揭示了一种Novel [1.2.4]triazolo[1,5-a]pyrazine化合物，其化学式如下：这些化合物可以制备成药物组成物，并可用于哺乳动物包括人类的预防和治疗多种疾病，例如，但不限于疼痛、炎症等。
• Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases
  申请人：Andrews Inglis Martin James

  公开号：US20070281943A1

  公开（公告）日：2007-12-06

  Novel imidazo[1,2-a]pyrazine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, arthritis, inflammation, and others.

  本发明揭示了一种具有以下公式表示的新型咪唑并[1,2-a]吡嗪化合物： 这些化合物可以制备为药物组成物，并可用于预防和治疗哺乳动物，包括人类的各种疾病，包括但不限于关节炎，炎症等。